Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAFV600E Mutation-Reference-Cited by-同舟云学术

Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAFV600E Mutation

Published:2013-10 Issue:10 Volume:23 Page:1277-1283
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Kim Kevin B.¹,Cabanillas Maria E.²,Lazar Alexander J.³,Williams Michelle D.³,Sanders Deborah L.¹,Ilagan Joseph L.¹,Nolop Keith⁴,Lee Richard J.⁵,Sherman Steven I.²

Affiliation:

1. Department of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

2. Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

3. Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

4. Plexxikon Inc., Berkeley, California.

5. Roche Pharmaceuticals, Nutley, New Jersey.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2013.0057

Reference40 articles.

1. Cancer statistics, 2012

2. Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid

3. Dedifferentiated thyroid cancer: A therapeutic challenge

4. Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy

5. Cytotoxic Chemotherapy for Differentiated Thyroid Carcinoma

Cited by 177 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A computational approach to assessing the prognostic implications of BRAF and RAS mutations in patients with papillary thyroid carcinoma;Endocrine;2024-06-17

2. The Heinous Hobnail: A Case Report of the Rare Hobnail Variant of Papillary Thyroid Carcinoma;Cureus;2024-05-28

3. Decabromodiphenyl ether exposure reduces dabrafenib sensitivity of papillary thyroid carcinoma harboring BRAF mutation through the EGFR-CRAF-MAPK pathway: An in vitro study;Toxicology;2024-05

4. The Knockdown of FKBP Prolyl Isomerase 10 (FKBP10) Reverses Resistance in BRAFV600E Mutant Thyroid Papillary Cancer Cells;J BIOL REG HOMEOS AG;2024

5. Clinical responses to vemurafenib in postoperative recurrence of papillary thyroid carcinoma with esophageal fistula: A case report;Medicine;2024-03-15